Healio

Most dupilumab use for asthma, CRSwNP categorized as persistent

Please provide your email address to receive an email when new articles are posted on . 25% of patients experienced a gap of 60 days or more since they last filled their prescription. Patients with ...
Yahoo Finance

Regeneron’s Dupixent approved as first adolescent CRSwNP treatment

The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal ...
Monthly Prescribing Reference

Dupixent Approval Expanded to Include Adolescent Patients With CRSwNP

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...
Healio

Dupilumab outperforms omalizumab in CRSwNP with asthma

Please provide your email address to receive an email when new articles are posted on . Patients with both chronic rhinosinusitis with nasal polyps and asthma experience greater disease severity and ...
TipRanks on MSN

GSK’s depemokimab receives positive EMA opinion for severe asthma and CRSwNP

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for ...
The American Journal of Managed Care

New Guidance Supports 3 Therapies for CRSwNP

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis ...
The American Journal of Managed Care

Potential Relationship Found Between SERPINB10 Expression, CRSwNP Recurrence

This new study explored how expression of SERPINB10 may be related to postoperative recurrence of and inflammation related to chronic rhinosinusitis with nasal polyps (CRSwNP). SERPINB10, a ...
Fierce Pharma

GSK’s long-acting asthma med scores in suite of CHMP drug endorsements

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Monthly Prescribing Reference

FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...
PMLiVE

Sanofi/Regeneron’s Dupixent receives FDA approval for adolescents with CRSwNP

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal ...
Medscape

Head-to-Head Trial Finds Winner for CRSwNP With Asthma

Dupilumab significantly outperformed omalizumab in reducing the size of nasal polyps and improving sense of smell in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting ...
Yahoo Finance

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...